Philadelphia-based ExpressCells closed on its first series A funding in July. The genetic engineering company received $800,000 to build the commercial and operational infrastructure to sell its knock-in cell lines.
“This will allow us to market our novel plasmid technology that will give scientists better cell models for drug discovery and other research purposes,” said Matt Handel, co-founder and CEO of ExpressCells.
In collaboration with Temple University research, ExpressCells will potentially reduce the average time to insert new genes into a cell with CRISPR gene-editing techniques.
Article by PR Log